Effect of Fremanezumab on the Total Burden of Migraine in Patients with Episodic or Chronic Migraine: Findings from 3 Randomized, Double-blind, Placebo-controlled Phase 3 Studies (2439)
Christina Sun‐Edelstein(St Vincent's Hospital Melbourne), Jan Lewis Brandes(Merck & Co., Inc., Rahway, NJ, USA (United States)), Sanjay Gandhi(Kansas City VA Medical Center), Joshua M. Cohen(Tufts University), Steve Barash(Teva Pharmaceuticals (Australia))
Cited by 0
Related Papers
Drug-induced serotonin syndrome: a review
|Expert Opinion on Drug Safety|2008|169
Foods and Supplements in the Management of Migraine Headaches
|Clinical Journal of Pain|2009|146
The FDA Alert on Serotonin Syndrome With Use of Triptans Combined With Selective Serotonin Reuptake Inhibitors or Selective Serotonin‐Norepinephrine Reuptake Inhibitors: American Headache Society Position Paper
|Headache The Journal of Head and Face Pain|2010|126
Risk of medication overuse headache across classes of treatments for acute migraine
|The Journal of Headache and Pain|2016|115
Role of magnesium in the pathogenesis and treatment of migraine
|Expert Review of Neurotherapeutics|2009|100